ClinicalTrials.gg
CompletedNCT05853835Updated Jan 23, 2025

First-in-Human Trial in Healthy Adult Volunteers to Evaluate Safety, Tolerability and PK of LAPIX Study Drug; LPX-TI641

A Phase 1 interventional study of LPX-TI641 in Autoimmune Diseases and Multiple Sclerosis, sponsored by LAPIX Therapeutics Inc.. Completed at 2 sites in 2 countries. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-23.

Primary conditionMultiple SclerosisRegistry: Autoimmune DiseasesReclassifiedWhy we changed it
Registry
Autoimmune Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
Multiple Sclerosis
Why
  1. The study's listed conditions name Multiple Sclerosis, a narrower term within Autoimmune Diseases.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by LAPIX Therapeutics Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Aug 2024, 2 years 3 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,192 studies in Multiple Sclerosis with a site in United States — 184 open to participants now, 259 under way, 23 of them phase 3. Multiple Sclerosis · United States.

Enrollment
333rd of 879
72 · median 50
Started
2023
with 68 others
Phase 1
105 of 1,192
18 open now
Registered
986th of 1,192
by date

Among the 1,192 studies in Multiple Sclerosis with a site in United States, this one is the 333rd largest by enrollment of the 879 interventional ones that give a count, is one of 69 that started in 2023, is one of 105 in phase 1, and was the 986th registered.

Multiple Sclerosis

3,271 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

184 of the 1,192 studies in Multiple Sclerosis with a site in United States are open now. Recruiting first, the newest first:

179 more — sign in →

All 184 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 433 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,192 studies in Multiple Sclerosis with a site in United States, or all of them as a file.
02

Study summary

A Phase I First-in-Human, Randomized, Double-Blind, Placebo-Controlled Study in Healthy Adult Volunteers to Evaluate Safety, Tolerability, and Pharmacokinetics after Single and Multiple Oral Dose of LPX-TI641.

Read the detailed description

This is a first-in-human, multi center, randomized, double-blinded, single and multiple ascending doses (SAD and MAD) Phase I study in healthy adult volunteers (HV).

The SAD cohorts will consist of six cohorts of eight participants (6 randomized to treatment + 2 randomized to placebo) in each cohort (Total 48 HV). Additional cohorts may be added.

The MAD cohorts will consist of 3 cohorts of eight participants (6 randomized to treatment + 2 randomized to placebo) in each cohort (Total 24 HV). The subjects in MAD cohorts will be dosed once daily for 7 consecutive days. Additional cohorts may be added.

Each entire cohort of 8 HV subjects will be enrolled at the same site.

03

Conditions studied

  • Autoimmune Diseases
  • Multiple Sclerosis

Browse trials for

04

In context

Multiple Sclerosis Reclassified

3,271 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

This study's enrollment of 72 is above the median of 50 across 2,207 interventional studies indexed under Multiple Sclerosis.

Browse Multiple Sclerosis studies →

Lead sponsor

LAPIX Therapeutics Inc. is the lead sponsor of 4 studies on the registry; 1 is open to participants now.

Compared within Multiple Sclerosis, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Autoimmune Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria: Healthy volunteers

  1. Subject has signed an Form (ICF) prior to any study-specific procedures being performed
  2. Healthy volunteers (HV) with no known acute or chronic medical conditions (respiratory, gastrointestinal, renal, hepatic, hematological, lymphatic, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, endocrine, etc.) at the time of enrollment.
  3. Healthy volunteers (HV) with dermatological conditions are allowed if they are not receiving systemic treatments for their dermatological condition.
  4. All male and non-pregnant females aged 18-55 years old irrespective of their race and ethnicity.
  5. (BMI) 18.0-30.0 kg/m2, inclusive at screening.
  6. Clinical laboratory evaluations performed at screening, are within acceptable normal reference ranges (Grade 1 abnormalities may be acceptable if deemed necessary by the investigator. Grade 2 or higher would be exclusionary).
  7. Subjects who are willing and able to adhere to study protocol requirements including but not limited to scheduled outpatient visits, inpatient hospital stay, laboratory tests, and 12-lead .
  8. - All subjects (male and female) must agree to use any two of the highly effective contraception methods listed below. This criterion must be followed from the time of the first dose of study medication for 6 weeks after the last dose in females and for 90 days after the last dose for males.

    a. The following applies to all female volunteers with and female partners of male volunteers enrolled in the study.

    i. Implantable progestogen-only hormone contraception associated with inhibition of ovulation.

ii. Intrauterine device. iii. Intrauterine hormone-releasing system. iv. Bilateral tubal occlusion. v. Combined (estrogen- and progestogen-containing) hormonal contraception associated with inhibition of ovulation: 1) Oral 2) Intravaginal 3)Transdermal 4) Injectable vi. Progestogen-only hormone contraception (oral or injectable) is associated with inhibition of ovulation.

vii. Vasectomized partner viii. Sexual abstinence -this is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study intervention. The reliability of sexual abstinence needs to be evaluated about the duration of the study and the preferred and usual lifestyle of the participant.

b. The following applies to all male subjects in the study: i. Sexual abstinence- this is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study intervention. The reliability of sexual abstinence needs to be evaluated for the duration of the study and the preferred and usual lifestyle of the participant.

ii. A combination of male condoms with either cervical cap, diaphragm, or sponge with spermicide (double-barrier methods).

iii. Vasectomy

Exclusion Criteria: Healthy volunteers

  1. Any known history of
  2. Any known history of asthma
  3. COVID-19:

    The subject has COVID-19 positive status (confirmed by clinical signs and symptoms and a positive SARS-CoV-2 NAAT result COVID test) at any time during the screening period.

    OR has had recent COVID-19 vaccination including a booster dose in the past 30 days

    OR has received anti-viral therapy intended to prevent COVID-19 such as nelmetavir/ritonavir, remdesivir, molnupiravir, interferons, Anti-SARS-CoV-2 monoclonal antibodies, IVIG SARS-CoV-2, COVID-19 Convalescent plasma, etc. within the past 30 days

  4. Subject with positive results for (hepatitis B surface antigens) and/or HBcAb (Hepatitis B core antibodies) and/or Ab (hepatitis C antibodies), and/or Ab (human immunodeficiency virus antibodies).
  5. Blood loss of >250 mL or donated blood within 56 days or donated plasma within 7 days of screening.
  6. Recent vaccination with such as influenza, MMR, Herpes zoster, varicella, yellow fever, Rotavirus vaccine, etc., or inactivated vaccines such as Hepatitis A, Rabies vaccine, etc. in the past 30 days.
  7. Abnormal amylase levels (Grade 2 or greater)
  8. ECG abnormalities ( >450 ms for males and QTcF >470 ms for females).
  9. History of or current compulsive abuse of alcohol or positive test for alcohol at screening or Day 0 of Visit 1
  10. History of or current use of or positive test at screening or Day 0 of Visit 1 for drugs such as marijuana, cocaine, phencyclidine [PCP], crack, opioid derivatives including heroin, and amphetamine derivatives.
  11. Consumption of any beverages or food containing alcohol or drugs such as marijuana, cocaine, phencyclidine [PCP], crack, opioid derivatives including heroin, and amphetamine derivatives from screening until donating the last sample of the study
  12. Use of medications for the timeframes specified below, except for medications exempted by the Investigator on a case-by-case basis because they are judged unlikely to affect the PK profile of the study drug or subject safety (e.g., topical drug products without significant systemic absorption):

    • prescription medications within 14 days prior to dosing or 5 half-lives, whichever is longer;
    • over-the-counter products and natural health products (including herbal remedies homeopathic and traditional medicines, probiotics, food supplements such as vitamins, minerals, amino acids, essential fatty acids, and protein supplements used in sports) within 14 days prior to dosing or 5 half-lives, whichever is longer, except for the occasional use of paracetamol (up to 2 g daily);
    • any prescription or over-the-counter medication or natural health products used for the treatment of irregular bowel transit (e.g,. diarrhea, constipation) within 4 weeks prior to dosing;
    • depot injection or implant of any drug within 3 months prior to dosing;
    • use of any drugs known to induce or inhibit hepatic metabolism (including St. John's Wort [hypericin]) within 14 days prior to dosing.
  13. The subject has participated in another study involving any investigational product within 60 days, or 5 half-lives, whichever is longer, before the dose of the study drug.
  14. Pregnant or lactating women or women currently undergoing infertility treatments or women who intend to become pregnant during the time of study enrollment.
  15. Involvement in the planning and conduct of the study (applies to CRO staff or staff at the study site).
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
72 participants (actual)

Study arms

  • Experimental
    Cohort-1

    First dose of SAD cohort (6 treatment + 2 placebo)

    Drug: LPX-TI641

  • Experimental
    Cohort-2

    Second dose of SAD cohort (6 treatment + 2 placebo)

    Drug: LPX-TI641

  • Experimental
    Cohort-3

    Third dose of SAD cohort (6 treatment + 2 placebo)

    Drug: LPX-TI641

  • Experimental
    Cohort-4

    Fourth dose of SAD cohort (6 treatment + 2 placebo)

    Drug: LPX-TI641

  • Experimental
    Cohort-5

    Fifth dose of SAD cohort (6 treatment + 2 placebo)

    Drug: LPX-TI641

  • Experimental
    Cohort-6

    Sixth dose of SAD cohort (6 treatment + 2 placebo)

    Drug: LPX-TI641

  • Experimental
    Cohort-7

    First dose of MAD cohort (6 treatment + 2 placebo)

    Drug: LPX-TI641

  • Experimental
    Cohort 8

    Second dose of MAD cohort (6 treatment + 2 placebo)

    Drug: LPX-TI641

  • Experimental
    Cohort 9

    Third dose of MAD cohort (6 treatment + 2 placebo)

    Drug: LPX-TI641

Interventions

  • DrugLPX-TI641

    LAPIX Therapeutics Inc (LAPIX) has developed LPX-TI641, a small molecule for immune tolerance restoration/induction that is an orally bioavailable Tim family agonist (Tim-3 and Tim-4).

07

What researchers measure

Primary outcomes

  1. To evaluate the safety and tolerability after single ascending oral doses of LPX-TI641 in healthy adult volunteers.

    Proportion of subjects with AEs, SAEs and DLTs will be recorded.

    Time frame: 14 days

  2. To evaluate the safety and tolerability after multiple ascending oral doses of LPX-TI641 in healthy adult volunteers.

    Proportion of subjects with AEs, SAEs and DLTs will be recorded.

    Time frame: 21 days

Secondary outcomes

  1. To evaluate the plasma pharmacokinetics after single ascending oral doses of LPX-TI641 in healthy adult volunteers.

    Measurements of PK parameters including * Maximum observed plasma concentration (Cmax), * Time to first occurrence of Cmax (Tmax), * Area under the plasma concentration-time curve from time 0 to the time last concentration measurement (AUC0-last) * Area under the plasma concentration-time curve from time 0 to 24 hr (AUC0-24) * Area under the plasma concentration-time curve from time 0 to infinity (AUC0-∞), * Percentage AUC extrapolated (%AUCextrap) * Terminal disposition phase half-life (t1/2z), * Apparent clearance after extravascular administration (CL/F), * Apparent volume of distribution during the terminal phase after extravascular administration (Vz/F)

    Time frame: Day 1

  2. To evaluate the plasma pharmacokinetics after multiple ascending oral doses of LPXTI641 in healthy adult volunteers.

    Measuring the PK parameters such as Cmax, Tmax, AUC0-last, AUC0-24, %AUCextrap, t1/2, CL/F, Vz/F at steady state * Minimal observed concentration within the dosing interval (Ctrough) * Accumulation index (Cmax and AUC)

    Time frame: Day 1 and Day 7

08

Study locations

2 sites
  • AXIS Clinicals
    Dilworth, Minnesota 56529, United States
  • Triumpharma clinical research unit at Alessra Hospital
    Amman, Jordan
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2023 to primary completion in Aug 2024, 9 months.

Of 39 industry-sponsored phase 1 interventional studies under Multiple Sclerosis, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 32. This study's 9 months is below that.

Counting every sponsor, half of 92 studies reached it within 30 months; a quarter within 9 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2023
First posted
May 11, 2023
StartActual
Oct 30, 2023
Primary completionActual
Aug 15, 2024
CompletionActual
Nov 1, 2024
Last update
Jan 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05853835
Lead sponsor
LAPIX Therapeutics Inc.
Responsible party
Sponsor
First posted
May 11, 2023
Start date
Oct 30, 2023
Primary completion
Aug 15, 2024
Completion
Nov 1, 2024
Last update
Jan 23, 2025

Study contacts

Mustafa Mahmoud Shennak, MD
principal investigator · Triumpharma
John Mickelson, DO
principal investigator · AXIS Clinicals, Dilworth, Minnesota USA

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion